Antisense Molecules for Consistent Exon Skipping in Dystrophin Gene
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antisense oligonucleotide therapies for genetic disorders, such as Duchenne Muscular Dystrophy, face challenges in consistently and efficiently inducing exon skipping, particularly due to the complexity of targeting specific splicing sites and the variability in efficacy among different antisense molecules.
Innovation Solution
Development of specific antisense molecules capable of binding to selected RNA motifs involved in the splicing of pre-mRNA to induce efficient and consistent exon skipping, using cocktails of oligonucleotides targeting specific exons in the dystrophin gene transcript, and optimizing delivery methods for therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antisense oligonucleotides are used to target specific splicing sites, then exon skipping can be induced, but the complexity of targeting and variability in efficacy among different molecules make consistent and efficient induction difficult
Solution Approach 1:
The invention divides the complex targeting problem into multiple discrete components by using a library of antisense oligonucleotides, each targeting specific splice site motifs. This segmentation allows systematic evaluation and selection of optimal targets, improving reliability while managing complexity through modular design.
Solution Approach 2:
The invention optimizes multiple parameters of the antisense oligonucleotides including length, sequence composition, and binding site location to maximize exon skipping efficiency. By systematically varying these parameters across different molecules in the library, consistent and reliable exon skipping is achieved despite the complexity of the targeting process.
2Productivity
If antisense molecules are designed to bind RNA motifs involved in splicing, then exon skipping efficiency improves, but the precision required to target specific exons increases difficulty
Solution Approach 1:
The invention replaces complex mechanical targeting systems with a molecular approach using chemically synthesized antisense oligonucleotides that bind to specific RNA motifs. This substitution simplifies the targeting mechanism while maintaining high precision through complementary base pairing, thereby improving exon skipping efficiency without proportionally increasing targeting difficulty.
Solution Approach 2:
The antisense oligonucleotides serve as intermediary molecules that mediate between the therapeutic goal (exon skipping) and the molecular target (splice site motifs). These intermediaries provide a controllable and measurable link, improving efficiency while facilitating precise targeting through well-defined binding interactions.
3Reliability
If therapeutic doses of antisense molecules are administered, then treatment efficacy is achieved, but the cost and complexity of delivery methods increase
Solution Approach 1:
The invention develops a universal platform of antisense oligonucleotides that can be delivered through standardized therapeutic formulations. This multi-functional approach allows the same delivery system to be used across different exon skipping applications, improving therapeutic efficacy while reducing the complexity of delivery methods through standardized protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enables robust and consistent exon skipping at low therapeutic doses, effectively addressing the limitations of previous therapies by improving the precision and efficiency of antisense-mediated splicing modulation, potentially leading to improved treatment outcomes for genetic disorders like Duchenne Muscular Dystrophy.
Implementation Method 1
antisense molecules capable of binding to a selected target to induce exon skipping
Data Source
AI summary
An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.